Should these results prove to be accurate, it means that scientists have actually managed to create a way to reverse aging.
Read more
Category: biotech/medical – Page 2,647
People who received regular lifestyle counseling online were able to lower their blood pressure as much as a medication would, researchers said Saturday.
Their study involved 264 people with high blood pressure and an average age of 58.
The subjects’ average blood pressure began at around 140/90 mmHg, meaning they had what is clinically known as stage 1 hypertension.
Read more
A team of researchers from Sweden, France, Belgium and Switzerland has found a way to reverse resistance to an antibiotic drug used to treat tuberculosis. In their paper published in the journal Science, the team describes how they screened compounds that activated different pathways to activate ethionaide, a compound used to treat tuberculosis.
The researchers are currently working with GlaxoSmithKline and Biotech Bioversys to further develop the small prototype molecule into a drug that can be mass produced and sold.
(Medical Xpress)—A team of researchers from Sweden, France, Belgium and Switzerland has found a way to reverse resistance to an antibiotic drug used to treat tuberculosis. In their paper published in the journal Science, the team describes how they screened compounds that activated different pathways to activate ethionaide, a compound used to treat tuberculosis.
The development of antibiotics to treat bacterial infections has very clearly made the world a healthier place. Unfortunately, over time, bacteria have been evolving to thwart such compounds, putting us all at risk once again. Because of that, scientists have been searching for new treatments, or in some cases, ways to make old treatments work again using new techniques. In this new effort, the researchers have found a way to make ethionaide, a prodrug (a compound that is metabolized in the body to produce a desired drug), become effective again in patients infected with resistant strains of Mycobacterium tuberculosis.
Ethionaide was developed back in the late 1950s as a treatment for tuberculosis. It is activated by an enzyme called EthA found in the bacteria—once activated, ethionaide attacks the bacteria. Over time, many strains of M. tuberculosis have become resistant to ethionaide by developing EthA mutations that do not activate the compound, making it useless as a treatment. To get around this problem, the researchers searched for and found a prototype molecule called SMARt-420 that activates ethionaide by taking a different route—interacting with a secondary gene. The team has found that giving patients a dose of the small molecule after administering a dose of ethionaide restored the lattter’s ability to destroy a range of M. tuberculosis—testing showed it reduced the bacterial load found in patient lungs after just three weeks—similar to the effectiveness of ethionaide alone against M. tuberculosis prior to the develop of resistance.
Read more
President Donald Trump has signed a bill authorizing $19.5 billion in funding for NASA, which includes an increased focus on deep space exploration and a new goal of a manned mission to Mars.
The NASA Transition Authorization Act of 2017, or S. 442, provides funding for fiscal year 2018, which begins October 1. It specifically appropriates money for NASA’s deep space exploration, including the Space Launch System and the Orion spacecraft, as well as for the ongoing medical monitoring and treatment of astronauts. It builds on the current public-private partnership for space, with commercial companies transporting American astronauts to the International Space Station (ISS) and NASA focusing on deep space and the mission to Mars.
Read more
#ZoomVision
Posted in biotech/medical
“Yep, transforming health care and telepathy, those are the items on her to-do list. Jepsen plans to achieve both goals with a cheap wearable device that her engineers are now tinkering with in the lab. And then there’s the side benefit of reinvigorating the tired consumer electronics industry, which Jepsen thinks is due for the next big thing.
Jepsen was at SXSW to give a talk about Openwater, her new startup. While the company is still conducting R&D to decide on its first products, Jepsen feels the need to speak out now about what she’s building and how she thinks her technology could radically change society. She wants to give people fair warning and time to think about what’s coming. “I know it seems outlandish to be talking about telepathy, but it’s completely solid physics and mathematical principles—it’s in reach in the next three years,” she says.
Plus, she’s sick of stealth mode. “I haven’t been able to to talk about what I’ve been doing for five and half years while I was at Google and Facebook, and I don’t think secrecy is useful,” she says. She left Facebook in August, and in September she filed patents for her Openwater technology, which she expects to be issued any day now.
Read more
Toronto-based eSight Corp. has launched a pair of electronic glasses that allow the legally blind to see. The eSight3 glasses use high-tech image processing to give those who are legally blind the chance to experience what it is like to have 20/20 vision.
Users can control a variety of functions that are important for vision, including magnification, contrast, brightness and focus. Videos projected onto two OLED screens in front of the eyes allow the user to see the different functions in action.
ESight glasses are ideal for a number of conditions, including for people who have optic nerve hypoplasia, ocular albanism, forms of glaucoma and more, according to the company.
Read more